| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2042119 | Cell Reports | 2013 | 14 Pages |
SummaryThe IL-6-triggered positive feedback loop for NFκB signaling (or the IL-6 amplifier/Inflammation amplifier) was originally discovered as a synergistic-activation signal that follows IL-17/IL-6 stimulation in nonimmune cells. Subsequent results from animal models have shown that the amplifier is activated by stimulation of NFκB and STAT3 and induces chemokines and inflammation via an NFκB loop. However, its role in human diseases is unclear. Here, we combined two genome-wide mouse screens with SNP-based disease association studies, revealing 1,700 genes related to the IL-6 amplifier, 202 of which showed 492 indications of association with ailments beyond autoimmune diseases. We followed up on ErbB1 from our list. Blocking ErbB1 signaling suppressed the IL-6 amplifier, whereas the expression of epiregulin, an ErbB1 ligand, was higher in patients with inflammatory diseases. These results indicate that the IL-6 amplifier is indeed associated with human diseases and disorders and that the identified genes may make for potential therapeutic targets.
Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► The IL-6 amplifier is associated with various human diseases and disorders ► Genome-wide screens can isolate IL-6-amplifier-related genes ► These genes include those associated with human diseases ► Identified genes, e.g., the epiregulin-ErbB1 axis, may be therapeutic targets
